SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Abgenix, Inc. (ABGX)
An SI Board Since December 1998
Posts SubjectMarks Bans
590 38 0
Emcee:  Henry Niman Type:  Unmoderated
Introduction Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
540Makes sense to me.rkrw-11/10/2005
539It's word for word correct, John, written by Ende.tom pope-11/10/2005
538Merrill on abgx - <b>Caution - I cannot prove that Merrill really wrote John McCarthy-11/10/2005
537A Special Drug Just for You, at the End of a Long Pipeline [NYT] Message 218652Doc Bones-11/9/2005
536<i>No absolute need for phase 2+ in exact setting for off label usage/paymDewDiligence_on_SI-11/9/2005
535to serendipity: And I am for stopping smoking too. :) to Dew: <phase 2>kenhott-11/9/2005
534<i>A so called BiotechStockBlogger assesses the data and decides Erbitux iDewDiligence_on_SI-11/9/2005
533I agree with you about IMCL’s patent (it’s not worth much), but I disagree on thDewDiligence_on_SI-11/9/2005
532"better than Avastin" caution - because CONTEXT is everything ...... John McCarthy-11/8/2005
531Nov 8th remarks by Roger Perlmutter UPDATE 1-Reuters Summit-Amgen confident of John McCarthy-11/8/2005
530A so called BiotechStockBlogger assesses the data and decides Erbitux is in troutuck-11/8/2005
529RE: the decision points should be: efficacy, costs, and quality of life. I agreserendipity101-11/8/2005
528Poster Sessions - AACR-NCI-EORTC AACR-NCI-EORTC International Conference on MoJohn McCarthy-11/8/2005
527After reading some of the analyst reports, I can see that most of them are not okenhott-11/7/2005
526<i>>We note that the 46% improvement is in tumor progression rate, NOT DewDiligence_on_SI-11/5/2005
525Han Li, Ph.D., 212.319.3808 • This is what ABGX/AMGN reported yesterday: PaniJohn McCarthy-11/5/2005
524Yes, 'blinded' is preferred for PFS according to the guidance. But Permkeokalani'nui-11/5/2005
523Below is a list of abstracts presented at ECCO .... they are limited to ErbituxJohn McCarthy-11/5/2005
522Astonishingly, that Citi report does not mention that there are no clinical dataDewDiligence_on_SI-11/5/2005
521Citi: Pmab to Become EGFR MAb of Choice; Raising ABGX Target Price to $17 Novemopgcw-11/5/2005
520One more thing, For very good reason Mike King (from CC, Thanks J.S.) asked forMiljenko Zuanic-11/4/2005
519Wilder, GS guy got things wrong, imo. 75% is number of the pts in BSC group tMiljenko Zuanic-11/4/2005
518Miljenko, From what mopgcw (thanks!) just posted. Sorry I was a little off (bykeokalani'nui-11/4/2005
517GS: AMGN(OP/N)/IMCL(OP/N)/ABGX(IL/N): IMCL oversold. Panitumumab data favorable mopgcw-11/4/2005
516MJ - thank you very much for taking the time to reply and explain .... based oJohn McCarthy-11/4/2005
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News